Last reviewed · How we verify
testosterone gel 2%
At a glance
| Generic name | testosterone gel 2% |
|---|---|
| Also known as | EN3350, tostran, Axiron, LY900011 |
| Sponsor | Endo Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
- Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (PHASE1)
- Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance (PHASE4)
- Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc (PHASE2)
- Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism (PHASE4)
- Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (PHASE2)
- Testosterone Therapy in Castration Resistant Prostate Cancer (EARLY_PHASE1)
- Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |